These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38246099)
1. Herbal-based compounds: A review on treatments of cryptosporidiosis. Namazi F; Razavi SM Int J Parasitol Drugs Drug Resist; 2024 Apr; 24():100521. PubMed ID: 38246099 [TBL] [Abstract][Full Text] [Related]
2. Cryptosporidium and cryptosporidiosis. Soave R; Armstrong D Rev Infect Dis; 1986; 8(6):1012-23. PubMed ID: 3541121 [TBL] [Abstract][Full Text] [Related]
3. What is Cryptosporidium? Reappraising its biology and phylogenetic affinities. Barta JR; Thompson RC Trends Parasitol; 2006 Oct; 22(10):463-8. PubMed ID: 16904941 [TBL] [Abstract][Full Text] [Related]
8. Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Khan SM; Bajwa MR; Lahar RY; Witola WH Antimicrob Agents Chemother; 2023 Oct; 67(10):e0056923. PubMed ID: 37655889 [No Abstract] [Full Text] [Related]
9. Cryptosporidiosis and immune enteropathy: a review. Ma P Curr Clin Top Infect Dis; 1987; 8():99-153. PubMed ID: 3077284 [No Abstract] [Full Text] [Related]
10. [Research progress on nutrient transport and metabolism of Cryptosporidium]. Wang JH; Xue XH; Li PY Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2010 Dec; 28(6):451-4. PubMed ID: 21500534 [TBL] [Abstract][Full Text] [Related]
12. Host cells with transient overexpression of MDR1 as a novel in vitro model for evaluating on-target effect for activity against the epicellular Cryptosporidium parasite. Yang B; Wang D; Liu M; Wu X; Yin J; Zhu G J Antimicrob Chemother; 2021 Dec; 77(1):124-134. PubMed ID: 34648615 [TBL] [Abstract][Full Text] [Related]
13. Cryptosporidium excystation and invasion: getting to the guts of the matter. Smith HV; Nichols RA; Grimason AM Trends Parasitol; 2005 Mar; 21(3):133-42. PubMed ID: 15734661 [TBL] [Abstract][Full Text] [Related]
14. Anti-Cryptosporidial Drug-Discovery Challenges and Existing Therapeutic Avenues: A "One-Health" Concern. Ali M; Xu C; Nawaz S; Ahmed AE; Hina Q; Li K Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38255695 [TBL] [Abstract][Full Text] [Related]
15. Genetic richness and diversity in Cryptosporidium hominis and C. parvum reveals major knowledge gaps and a need for the application of "next generation" technologies--research review. Jex AR; Gasser RB Biotechnol Adv; 2010; 28(1):17-26. PubMed ID: 19699288 [TBL] [Abstract][Full Text] [Related]
16. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. Yang B; Yan Y; Wang D; Zhang Y; Yin J; Zhu G PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011217. PubMed ID: 36972284 [TBL] [Abstract][Full Text] [Related]
17. Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies. Jex AR; Smith HV; Nolan MJ; Campbell BE; Young ND; Cantacessi C; Gasser RB Adv Parasitol; 2011; 77():141-73. PubMed ID: 22137584 [TBL] [Abstract][Full Text] [Related]